CILIATECH - Glaucoma Innovators received FDA approval for the Investigational Device Exemption (IDE) application to initiate a feasibility study in the US for their novel INTERCIL Uveal Spacer for glaucoma.
Published
Signal category
Legal & Regulatory
Quote
“CILIATECH - Glaucoma Innovators are thrilled to announce approval by the US Food and Drug Administration (FDA) of the company’s Investigational Device Exemption (IDE) application to initiate a feasibility study in the US of their novel INTERCIL® Uveal Spacer for glaucoma”
— CILIATECH - Glaucoma Innovators team
Company
CILIATECH - Glaucoma Innovators
Developing a new class of supraciliary implant for treating glaucoma
- Industry
- Medical Equipment Manufacturing
- Location
- Chavanod, FR
- Company size
- 22 employees
CILIATECH is a medtech company specialized in ophthalmology, developing a new class of implant to address the increasing need to treat glaucoma durably with a novel design. Founded in 2017 by ophthalmic surgeon and inventor Dr. Philippe Sourdille and Olivier Benoit, a veteran engineer and biotech entrepreneur, CILIATECH developed the CID (Cilio-scleral Inter-positioning Device) groundbreaking concept ‘CID’ is the first implant in the industry to reduce IntraOcular Pressure (IOP) without needing to access the anterior chamber or create a subconjunctival filtration bleb. The device is implanted as a standalone procedure and in the latest trial has demonstrated efficacy in IOP lowering in both open angle glaucoma (POAG) and in narrow angle glaucoma - the latter is a real industry first. Implantation can be combined with cataract removal too. The company is located near Annecy, France - a beautiful region in the Western Alps which has been described as ‘the Alpine Venice’ www.cilia.tech
Founded 2017